ENDOMETRIAL LESIONS IN PATIENTS UNDERGOING TAMOXIFEN THERAPY
ENDOMETRIAL LESIONS IN PATIENTS UNDERGOING TAMOXIFEN THERAPY
复制标题
DOI：
10.1016/0020-7292(91)90767-y
复制
发表时间：
1991-10-01
影响因子：
3.8
通讯作者：
DEMUYLDER, E
中科院分区：
文献类型：
--
作者：
DEMUYLDER, X;NEVEN, P;DEMUYLDER, E
46 名未进行子宫切除的女性在 6-36 个月期间接受了他莫昔芬作为乳腺癌辅助治疗，并接受了宫腔镜检查以评估该药物对子宫内膜的影响。 23 名患者子宫内膜正常，其中 13 名患有子宫内膜息肉，8 名患有子宫内膜增生，2 名患有腺癌。 子宫内膜病变发生率与他莫昔芬的累积剂量直接相关，但接受孕激素治疗的患者与未接受孕激素治疗的患者相比，没有统计学差异。
Forty-six nonhysterectomized women treated with tamoxifen during 6-36 months as adjuvant therapy for breast cancer underwent a hysteroscopy to assess the endometrial effects of this drug. Whereas the endometrium was normal among 23 patients, 13 presented with endometrial polyps, 8 with hyperplasia and 2 with adenocarcinoma. The rate of endometrial lesions was directly related to the cumulative dose of tamoxifen but it was not statistically different among patients receiving progestational therapy compared to patients who did not receive this therapy.